Solid Biosciences (SLDB) Expected to Announce Quarterly Earnings on Monday

Key Points

• Solid Biosciences is expected to report Q3 2026 earnings before the market opens on Monday, November 2. Analysts project a loss of $0.37 per share; the company’s conference call is scheduled for November 6 at 4:00 p.m. ET.
• The company reported a Q2 loss of $0.38 per share, beating the consensus estimate of a $0.46 loss. Analysts expect full-year and next-year losses of $1.66 and $1.70 per share, respectively.
• SLDB recently traded at $5.92, well below its 50-day and 200-day moving averages near $8.15. Despite mixed ratings, the stock carries a “Moderate Buy” consensus and an average analyst price target of $18.79.

Solid Biosciences (NASDAQ:SLDB - Get Free Report) is projected to post its Q3 2026 results before the market opens on Monday, November 2nd. Analysts expect the company to announce earnings of ($0.37) per share for the quarter. Investors can find conference call details on the company's upcoming Q3 2026 earnings report for the latest details on the call scheduled for Friday, November 6, 2026 at 4:00 PM ET.

Solid Biosciences (NASDAQ:SLDB - Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.46) by $0.08. On average, analysts expect Solid Biosciences to post ($1.66) EPS for the current fiscal year and ($1.70) EPS for the next fiscal year.

Solid Biosciences Price Performance

NASDAQ SLDB opened at $5.92 on Monday. The stock has a market capitalization of $634.74 million, a P/E ratio of -3.10 and a beta of 2.47. The firm's 50-day moving average is $8.14 and its two-hundred day moving average is $8.15. Solid Biosciences has a 12 month low of $3.79 and a 12 month high of $11.45.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on SLDB shares. Loop Capital set a $25.00 price target on shares of Solid Biosciences in a research note on Monday, September 14th. Royal Bank Of Canada initiated coverage on shares of Solid Biosciences in a report on Wednesday, September 16th. They issued an "outperform" rating and a $18.00 price objective on the stock. HC Wainwright reaffirmed a "buy" rating and set a $25.00 price objective on shares of Solid Biosciences in a research report on Monday, September 14th. Wall Street Zen upgraded shares of Solid Biosciences from a "strong sell" rating to a "sell" rating in a report on Saturday, July 4th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Solid Biosciences in a report on Thursday, October 15th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $18.79.

About Solid Biosciences

Solid Biosciences Inc NASDAQ: SLDB is a biotechnology company focused on developing gene therapies for neuromuscular and other serious genetic diseases. The company uses adeno-associated virus (AAV) delivery technologies and genetic medicine approaches to develop treatments intended to address the underlying causes of disease.

Its lead investigational program, SGT-003, is being developed as a gene therapy for Duchenne muscular dystrophy, a severe X-linked muscle-wasting disorder. Solid Biosciences also has additional preclinical and clinical programs targeting other neuromuscular conditions, including diseases associated with defects in muscle proteins.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.